| Post-PL | Post-IB | |
| FEV1 (l) | 2.30 (0.60), (83%) | 2.46 (0.59), (88%)* |
| ΔFEV1 (l) | 0.07 (0.09), (3%)† | 0.26 (0.19), (9%)†‡ |
| FVC (l) | 4.07 (1.13), (103%) | 4.20 (1.17), (106%)* |
| ΔFVC (l) | 0.02 (0.18), (1%) | 0.23 (0.21), (6%)†‡ |
| FEV1/FVC (%) | 57 (7), (81%) | 59 (7), (83%) |
| ΔFEV1/FVC (%) | 1.3 (2.0), (2%)† | 2.9 (3.2), (4%)† |
| Tlco (ml/min/mm Hg) | 21.0 (6.2), (94%) | 20.2 (6.5), (90%) |
| ΔTlco (ml/min/mm Hg) | −0.1 (1.4), (−1%) | −1.1 (2.3), (−5%) |
| MIP (cm H2O) | 96 (20), (120%) | 98 (21), (121%) |
| ΔMIP (cm H2O) | −1 (11), (−2%) | 1.6 (7.7), (1%) |
| MEP (cm H2O) | 148 (54), (82%) | 148 (48), (83%) |
| ΔMEP (cm H2O) | 1 (12), (1%) | −6 (13), (−10%) |
| TLC (l) | 7.16 (1.49), (114%) | 7.04 (1.42), (112%) |
| ΔTLC (l) | −0.03 (0.26), (−1%) | −0.15 (0.20), (−3%)† |
| RV (l) | 2.73 (0.34), (125%) | 2.49 (0.47), (113%)* |
| ΔRV (l) | −0.14 (0.19), (−6%)† | −0.38 (0.22), (−19%)†‡ |
| FRC (l) | 4.05 (0.71), (121%) | 3.90 (0.82), (115%)* |
| ΔFRC (l) | −0.07 (0.17), (−2%) | −0.27 (0.29), (−9%)†‡ |
| IC (l) | 3.10 (1.01), (106%) | 3.15 (0.86), (109%) |
| ΔIC (l) | 0.04 (0.19), (1%) | 0.12 (0.32), (4%) |
| sRaw (cm H2O.s) | 12.7 (4.3), (301%) | 9.3 (4.6), (220%)* |
| ΔsRaw (cm H2O.s) | −0.6 (1.7), (−15%) | −4.7 (3.5), (−111%)†‡ |
Values are mean (SD), (% predicted normal values).
*p<0.05, post-IB vs post-PL.
†p<0.05 post-dose vs pre-dose within treatment.
‡p<0.05 IB vs PL post-dose minus pre-dose differences.
Δ, post-dose minus pre-dose difference; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; IC, inspiratory capacity; MIP, maximal inspiratory pressure; MEP, maximal expiratory pressure; PEF, peak expiratory flow; RV, residual volume; sRaw, specific airway resistance; SVC, slow vital capacity; TLC, total lung capacity; Tlco, carbon monoxide transfer factor.